
Kokua Line: With dashboard down, where is Hawaii's COVID-19 data?
Answer : Yes, although not with such specificity. The Hawaii Respiratory Disease Activity Summary, at, shows an uptick in COVID-19 cases statewide, with disease activity (percent positivity ) described as 'medium ' as of mid-July. COVID-19 was a factor in 2 % of all visits to hospital emergency departments on July 12, double the 1 % found on June 14, according to the summary, which we checked Tuesday.
The COVID-19 dashboards you relied on, and which are no longer being updated, summarized the number of COVID-19 cases statewide and by county on a weekly basis, and also provided data about vaccination, hospitalization and mortality rates, including by age and ethnicity.
The state Department of Health is changing its COVID-19 dashboards 'as we transition to our new data visualization platform. Our previous dashboards will no longer be updated, but new dashboards will be added over the next few weeks, ' according to a message on the DOH website dated June 18.
We asked a DOH spokesperson Tuesday when the new dashboards will be published, and what data categories they will include ; we'll publish the response when we receive it. Several readers have asked similar questions, seeking detailed information about the continuing effects of the virus.
Q : Regarding the scuttling of the Falls of Clyde, what about stuff inside the ship ? There's probably plenty that could be salvaged.
A : Yes, the state Department of Transportation says it worked with a maritime archaeologist last year to catalog and remove historical items from the nearly 147-year-old vessel, which is due to be scuttled in late November at least 12 miles due south of Honolulu Harbor. The salvaged artifacts are stored in a secured facility, the DOT said in a news release Monday.
The Falls of Clyde was designated a National Historic Landmark in 1989 as the world's only surviving four-masted fully-rigged ship, but despite preservation efforts the vessel deteriorated so badly over the years that it lost that designation in 2024, when it was deemed a safety and environmental hazard at imminent risk of sinking, according to the National Park Service, .
Docked at Honolulu Harbor since 2008 (now at Pier 7 ), the ship will undergo work for the next few months to make it tow-worthy and then be disposed of at sea, according to the news release, which said that Shipwright LLC, a Florida-based maritime technical consulting firm, has been hired to oversee the job.
Q : With the passage of the 'One Big Beautiful Bill, ' is it too late to get the electric car rebate ?
A : No, you would need to buy or lease an eligible electric vehicle by Sept. 30 to claim a federal tax credit of up to $7, 500 for a new vehicle or $4, 000 for a used one. Find details at fuel economy.gov /feg /taxcenter.shtml.
Mahalo Much mahalo to Officer Vegas from the Pearl City Police Station, who was very helpful in assisting my recently widowed mother with her tire pressure situation this past Thursday near the Iwilei Costco Tire Center. Kudos for doing a simple act of kindness for a person of the community, exemplifying the Honolulu Police Department motto, 'serving and protecting with aloha.'—Many thanks, S.K.------------Write to Kokua Line at Honolulu Star-Advertiser, 500 Ala Moana Blvd., Suite 2-200, Honolulu, HI 96813 ; call 808-529-4773 ; or email.------------
Solve the daily Crossword

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.